Mibispect

Copper Tetramibi Tetrafluoroborate, the active ingredient in Mibispect, is a copper‑based compound presented as an intravenous formulation for use in clinical settings. Its therapeutic role is currently under investigation, primarily in the context of antimicrobial research and potential infection management.

GNH USA supplies Mibispect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide. The company adheres to stringent quality standards and regulatory requirements.

Mibispect (Copper Tetramibi Tetrafluoroborate) is presently not approved for specific therapeutic indications, and its clinical use is limited to investigational settings.

- Investigational use: evaluated in clinical trials for resistant bacterial infections - Research use: studied for potential antifungal activity - Preclinical studies: assessed for anti‑parasitic potential

Common Side Effects: - Infusion‑related reactions: flushing, warmth, or mild rash - Nausea or vomiting - Headache - Transient elevation of liver enzymes - Mild electrolyte disturbances - Localized pain at the injection site

Serious or Rare Side Effects: - Anaphylactic shock or severe hypersensitivity - Acute renal impairment or failure - Significant hepatic dysfunction - Severe hypotension or cardiovascular collapse - Copper overload leading to neurotoxicity - Hemolytic anemia

Mibispect should be administered only under the supervision of qualified healthcare professionals. - Renal function: assess baseline kidney parameters before infusion - Hepatic function: monitor liver enzymes during treatment - Allergy history: screen for prior copper or metal hypersensitivity - Concomitant nephrotoxic agents: use with caution and monitor renal markers - Pregnancy and lactation: avoid unless benefits outweigh potential risks - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Copper Tetramibi Tetrafluoroborate may interact with several drug classes.

Major Interactions (Avoid): - Other copper‑containing products: risk of copper toxicity - Strong chelating agents (e.g., EDTA, dimercaprol): may reduce efficacy - Nephrotoxic antibiotics (e.g., aminoglycosides): increase renal risk

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor coagulation parameters - Hepatotoxic drugs (e.g., isoniazid): observe liver function tests - Other intravenous electrolytes: watch for electrolyte imbalances